The busy week for the idiopathic pulmonary fibrosis (IPF) space has continued apace with the news that Roche is selling off rights to one of the two drugs currently approved for the debilitating and fatal lung disease.
Key Takeaways
- As Roche sells Esbriet rights, a new generation of IPF drugs are emerging
- The lead candidate is Boehringer's recently-filed nerandomilast, its successor to Ofev
Roche bought InterMune for $8.3bn over a decade ago to get hold of Esbriet (pirfenidone) and has now sold the business and the US rights to the IPF drug to Legacy Pharma, a Cayman Islands-domiciled business that sells branded generics
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?